SLC38A1 and cancer: For the next step, we will investigate changes in glutamine metabolism by up- and down-regulating glutamine transporter proteins (e.g., ASCT2, SNAT1 and SNAT2) following CAP treatment to improve our understanding about the detailed roles of glutamine in CAP-based cancer therapy.